|Bid||25.96 x 800|
|Ask||30.41 x 800|
|Day's Range||25.34 - 26.09|
|52 Week Range||11.12 - 31.25|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Gov. Inslee has raised $2.3 million this year, with more than $1 million of that coming from donors in the Evergreen State.
SEATTLE, May 30, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
Business Journal Managing Editor Rob Johnson takes readers through a recap of Seattle business news. We call it Business Journal Untucked.
SEATTLE, May 15, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products,.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
NanoString (NSTG) delivered earnings and revenue surprises of -6.15% and 8.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE (AP) _ NanoString Technologies Inc. (NSTG) on Thursday reported a loss of $21.9 million in its first quarter. On a per-share basis, the Seattle-based company said it had a loss of 69 cents. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 65 cents per share.
SEATTLE, May 09, 2019 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today.
Business Journal Managing Editor Rob Johnson takes readers for a casual tour of the week that was. We call it Business Journal Untucked.
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
NanoString (NSTG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.
Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.
With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.
Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.
ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.
Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.
Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.